Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Akebia Therapeutics, Inc.AKBA · Entity 6105 | SVP, Chief Operating Officer | May 13, 2024 | May 14, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Akebia Therapeutics, Inc.
Report date May 13, 2024 · Filed May 14, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 672,092 |
Reported balance
After 2024-05-13 transaction · row 1
1 source rowRow 1 · 2024-05-13 · Sale · Disposed 34,840 · Balance 672,092 F1: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on May 12, 2023. F2: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on May 12, 2023.
F2: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 13, 2024 Filed May 14, 2024 16:04 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 34,840 | $1.26 | $43,898.40 |
DisclosureSEC source: 0001562180-24-004025 · primarydocument.xml · nonDerivative · entry 1 Dahan Michel · CIK 0001669737 · SVP, Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 672,092 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on May 12, 2023. F2 · shares: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2023. Read SEC document |
| February 29, 2024 Filed Mar 1, 2024 17:49 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 8,661 | $1.58 | $13,684.38 |
DisclosureSEC source: 0001562180-24-002023 · primarydocument.xml · nonDerivative · entry 1 Dahan Michel · CIK 0001669737 · SVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 706,932 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2022. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 18:02 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 10,744 | $1.52 | $16,330.88 |
DisclosureSEC source: 0001562180-24-001994 · primarydocument.xml · nonDerivative · entry 1 Dahan Michel · CIK 0001669737 · SVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 715,593 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 26, 2021. Read SEC document |
| January 31, 2024 Filed Feb 2, 2024 16:11 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 224,000 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001562180-24-000978 · primarydocument.xml · derivative · entry 2 Dahan Michel · CIK 0001669737 · SVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 224,000 Underlying: Common Stock · 224,000 shares Expires 2034-01-31 F3 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| January 31, 2024 Filed Feb 2, 2024 16:11 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 149,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-000978 · primarydocument.xml · nonDerivative · entry 1 Dahan Michel · CIK 0001669737 · SVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 726,337 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date. F2 · balance_after: Includes 1,500 shares of the Issuer's common stock purchased on June 30, 2023 and 1,500 shares of the Issuer's common stock purchased on December 29, 2023, each under the Issuer's Amended and Restated 2014 Employee Stock Purchase Plan. Read SEC document |
| May 25, 2023 Filed May 25, 2023 21:01 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 95,478 | $1.22 | $116,760.05 |
DisclosureSEC source: 0001562180-23-004503 · primarydocument.xml · nonDerivative · entry 2 Dahan Michel · CIK 0001669737 · SVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 574,037 F2 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of all of the PSUs. Read SEC document |
| May 24, 2023 Filed May 25, 2023 21:01 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantEmployee Stock Option (Right to buy) · Derivative | 200,000 | $0.00 Strike: $0.41 | $0.00 |
DisclosureSEC source: 0001562180-23-004503 · primarydocument.xml · derivative · entry 3 Dahan Michel · CIK 0001669737 · SVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2032-05-12 F3 · derivative.exercise_date: As previously disclosed, in May 2022, the Reporting Person was granted performance-based options (the "Options") pursuant to the Issuer's 2014 Incentive Plan, as amended. The Options vest upon the closing of a significant transaction as defined in the award agreements. On May 24, 2023, the Company entered into a License Agreement, which transaction qualified as a significant transaction and closed on May 24, 2023. As a result, all of the shares subject to the Option vested on May 24, 2023. Read SEC document |
| May 24, 2023 Filed May 25, 2023 21:01 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-004503 · primarydocument.xml · nonDerivative · entry 1 Dahan Michel · CIK 0001669737 · SVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 669,515 F1 · shares: As previously disclosed, in May 2022, the Reporting Person was granted performance-based restricted stock units ("PSUs") pursuant to the Issuer's 2014 Incentive Plan, as amended. The PSUs vest upon the closing of a significant transaction as defined in the award agreement. On May 24, 2023, the Company entered into a License Agreement, which transaction qualified as a significant transaction and closed on May 24, 2023. As a result, all of the PSUs vested on May 24, 2023 Read SEC document |
| May 12, 2023 Filed May 16, 2023 16:09 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-004168 · primarydocument.xml · nonDerivative · entry 1 Dahan Michel · CIK 0001669737 · SVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 469,515 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 08:01 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 1,878 | $0.88 | $1,647.95 |
DisclosureSEC source: 0001562180-23-002198 · primarydocument.xml · nonDerivative · entry 3 Dahan Michel · CIK 0001669737 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,515 F3 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the performance-based restricted stock units that were previously reported for the Reporting Person on a Form 4 filed on March 18, 2021. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 08:01 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 10,476 | $0.88 | $9,192.69 |
DisclosureSEC source: 0001562180-23-002198 · primarydocument.xml · nonDerivative · entry 2 Dahan Michel · CIK 0001669737 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,393 F2 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2020. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 08:01 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 8,058 | $0.88 | $7,070.90 |
DisclosureSEC source: 0001562180-23-002198 · primarydocument.xml · nonDerivative · entry 1 Dahan Michel · CIK 0001669737 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,869 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2022. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 16:06 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 10,090 | $0.81 | $8,205.19 |
DisclosureSEC source: 0001562180-23-002039 · primarydocument.xml · nonDerivative · entry 1 Dahan Michel · CIK 0001669737 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,927 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 26, 2021. F2 · balance_after: Includes 1,500 shares of the Issuers common stock purchased on June 30, 2022, and 1,500 shares of the Issuers common stock purchased on December 30, 2022, each under the Issuer's 2014 Amended and Restated Employee Stock Purchase Plan. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 21:11 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 1,232 | $2.17 | $2,674.30 |
DisclosureSEC source: 0001562180-22-002163 · primarydocument.xml · nonDerivative · entry 5 Dahan Michel · CIK 0001669737 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,017 F5 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the performance-based restricted stock units that were previously reported for the Reporting Person on a Form 4 filed on March 18, 2021. F6 · balance_after: Includes 1,500 shares of the Issuers common stock purchased on June 30, 2021 and 1,500 shares of the Issuers common stock purchased on December 31, 2021, each under the Issuers 2014 Amended and Restated Employee Stock Purchase Plan. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 21:11 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 6,873 | $2.17 | $14,919.22 |
DisclosureSEC source: 0001562180-22-002163 · primarydocument.xml · nonDerivative · entry 4 Dahan Michel · CIK 0001669737 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,249 F4 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2020. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 21:11 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 6,873 | $2.17 | $14,919.22 |
DisclosureSEC source: 0001562180-22-002163 · primarydocument.xml · nonDerivative · entry 3 Dahan Michel · CIK 0001669737 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,122 F3 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2019. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:11 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantEmployee Stock Option (Right to buy) · Derivative | 200,000 | $0.00 Strike: $2.16 | $0.00 |
DisclosureSEC source: 0001562180-22-002163 · primarydocument.xml · derivative · entry 6 Dahan Michel · CIK 0001669737 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2032-02-28 F7 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:11 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-002163 · primarydocument.xml · nonDerivative · entry 2 Dahan Michel · CIK 0001669737 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,995 F2 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One-third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:11 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 6,555 | $2.15 | $14,124.71 |
DisclosureSEC source: 0001562180-22-002163 · primarydocument.xml · nonDerivative · entry 1 Dahan Michel · CIK 0001669737 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,995 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 26, 2021. Read SEC document |
| April 01, 2021 Filed Apr 1, 2021 20:33 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 1,211 | $3.40 | $4,117.40 |
DisclosureSEC source: 0001562180-21-002541 · primarydocument.xml · nonDerivative · entry 1 Dahan Michel · CIK 0001669737 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,550 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one third of the performance-based restricted stock units that were previously reported for the Reporting Person on a Form 4 filed on March 18, 2021. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 19:17 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 11,648 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-002355 · primarydocument.xml · nonDerivative · entry 1 Dahan Michel · CIK 0001669737 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,761 F1 · shares: As previously disclosed, in February 2020, the Reporting Person was granted performance-based restricted stock unit awards ("PSUs") pursuant to the Issuer's 2014 Incentive Plan, as amended. The PSUs vest in connection with the achievement of specified commercial and regulatory milestones. On February 25, 2021, the Company reported its financial results for the year ended December 31, 2020. Subsequently, in accordance with the terms of the grant, the Issuer's Compensation Committee certified the achievement of a commercial milestone and, as a result, one third of the reported PSUs will vest on each of March 31, 2021, February 28, 2022 and February 28, 2023, subject to the Reporting Person's continued service with the Issuer on each vesting date. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 16:08 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 7,945 | $3.40 | $26,982.01 |
DisclosureSEC source: 0001562180-21-001784 · primarydocument.xml · nonDerivative · entry 3 Dahan Michel · CIK 0001669737 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,113 F4 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2019. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 16:08 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 6,602 | $3.40 | $22,421.05 |
DisclosureSEC source: 0001562180-21-001784 · primarydocument.xml · nonDerivative · entry 2 Dahan Michel · CIK 0001669737 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,058 F3 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2020. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 16:08 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantEmployee Stock Option (Right to buy) · Derivative | 110,000 | $0.00 Strike: $3.46 | $0.00 |
DisclosureSEC source: 0001562180-21-001784 · primarydocument.xml · derivative · entry 4 Dahan Michel · CIK 0001669737 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2031-02-26 F5 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 16:08 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 62,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-001784 · primarydocument.xml · nonDerivative · entry 1 Dahan Michel · CIK 0001669737 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,660 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date. F2 · balance_after: Includes 1,500 shares of the Issuer's common stock purchased on June 30, 2020 and 1,200 shares of the Issuer's common stock purchased on December 31, 2020, each under the Issuer's 2014 Amended and Restated Employee Stock Purchase Plan. Read SEC document |
| February 28, 2020 Filed Mar 2, 2020 19:29 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 120,000 | $0.00 Strike: $8.87 | $0.00 |
DisclosureSEC source: 0001562180-20-001937 · primarydocument.xml · derivative · entry 3 Dahan Michel · CIK 0001669737 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2030-02-28 F3 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter. Read SEC document |
| February 28, 2020 Filed Mar 2, 2020 19:29 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 6,972 | $8.70 | $60,656.40 |
DisclosureSEC source: 0001562180-20-001937 · primarydocument.xml · nonDerivative · entry 2 Dahan Michel · CIK 0001669737 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,960 F2 · shares: This sale was made to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2019. Read SEC document |
| February 28, 2020 Filed Mar 2, 2020 19:29 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-001937 · primarydocument.xml · nonDerivative · entry 1 Dahan Michel · CIK 0001669737 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,932 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date. Read SEC document |
| April 11, 2019 Filed Apr 12, 2019 16:01 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | Disposition to issuerCommon Stock | 11,909 | $7.70 | $91,699.30 |
DisclosureSEC source: 0000899243-19-010590 · doc4.xml · nonDerivative · entry 1 Dahan Michel · CIK 0001669737 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,932 F1 · shares: The proceeds from the disposition of these shares are to be used by the reporting person to cover tax liabilities associated with previously vested restricted stock units. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 16:06 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantEmployee Stock Option (Right to buy) · Derivative | 100,000 | $0.00 Strike: $7.28 | $0.00 |
DisclosureSEC source: 0001562180-19-001677 · primarydocument.xml · derivative · entry 2 Dahan Michel · CIK 0001669737 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-02-28 F2 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 16:06 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-001677 · primarydocument.xml · nonDerivative · entry 1 Dahan Michel · CIK 0001669737 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,841 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date. Read SEC document |
| December 12, 2018 Filed Dec 13, 2018 08:14 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | Tax withholdingCommon Stock | 23,385 | $8.94 | $209,061.90 |
DisclosureSEC source: 0000899243-18-030793 · doc4.xml · nonDerivative · entry 1 Dahan Michel · CIK 0001669737 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,841 F1 · balance_after: Includes 2,000 shares of common stock inadvertently omitted from the reporting person's Form 3 filed on March 18, 2016. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 16:16 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantEmployee Stock Option (Right to buy) · Derivative | 27,500 | $0.00 Strike: $14.30 | $0.00 |
DisclosureSEC source: 0001562180-18-001386 · primarydocument.xml · derivative · entry 2 Dahan Michel · CIK 0001669737 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 27,500 shares Expires 2028-02-28 F2 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2014 Incentive Plan. 25% of the shares underlying this option will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 16:16 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 19,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-001386 · primarydocument.xml · nonDerivative · entry 1 Dahan Michel · CIK 0001669737 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,226 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan. One hundred percent of the restricted stock units will vest on the third anniversary of the grant date. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 16:20 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 1,398 | $19.64 | $27,456.72 |
DisclosureSEC source: 0001562180-17-003205 · primarydocument.xml · nonDerivative · entry 1 Dahan Michel · CIK 0001669737 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,826 F1 · shares: Shares sold by Reporting Person pursuant to a 10b5-1 plan to pay taxes in connection with the vesting of restricted stock pursuant to the December 23, 2013 restricted stock award. Read SEC document |
| September 28, 2017 Filed Oct 2, 2017 16:04 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 5,000 | $19.30 | $96,500.00 |
DisclosureSEC source: 0001562180-17-003085 · primarydocument.xml · nonDerivative · entry 1 Dahan Michel · CIK 0001669737 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,224 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 15, 2017. Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 16:06 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 5,000 | $15.00 | $75,000.00 |
DisclosureSEC source: 0001562180-17-002729 · primarydocument.xml · nonDerivative · entry 1 Dahan Michel · CIK 0001669737 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,224 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 15, 2017. Read SEC document |
| July 03, 2017 Filed Jul 6, 2017 12:25 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 1,399 | $14.26 | $19,946.52 |
DisclosureSEC source: 0001562180-17-002435 · primarydocument.xml · nonDerivative · entry 1 Dahan Michel · CIK 0001669737 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,224 F1 · shares: Shares sold by reporting person to pay taxes in connection with the vesting of restricted stock pursuant to a December 23, 2013 award. Twenty-five percent of the shares vested on December 2, 2014, and the remaining shares vest in equal quarterly installments through October 1, 2017. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.11 to $14.41, inclusive. The reporting person undertakes to provide Issuer, any security holder of Issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| April 03, 2017 Filed Apr 4, 2017 16:01 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 1,401 | $9.18 | $12,857.68 |
DisclosureSEC source: 0001562180-17-001431 · primarydocument.xml · nonDerivative · entry 1 Dahan Michel · CIK 0001669737 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,623 F1 · shares: Shares sold by reporting person to pay taxes in connection with the vesting of restricted stock pursuant to a December 23, 2013 award. Twenty-five percent of the shares vested on December 2, 2014, and the remaining shares vest in equal quarterly installments through October 1, 2017. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.15 to $9.24, inclusive. The reporting person undertakes to provide Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| February 21, 2017 Filed Feb 23, 2017 16:03 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 62,500 | $10.14 Strike: $0.00 | $633,750.00 |
DisclosureSEC source: 0001562180-17-000883 · primarydocument.xml · derivative · entry 2 Dahan Michel · CIK 0001669737 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2027-02-21 F2 · derivative.exercise_date: 25% of the shares underlying this option will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter. Read SEC document |
| February 21, 2017 Filed Feb 23, 2017 16:03 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 39,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-000883 · primarydocument.xml · nonDerivative · entry 1 Dahan Michel · CIK 0001669737 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,024 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan. One hundred percent of the restricted stock units will vest on the third anniversary of the grant date. Read SEC document |
| January 01, 2017 Filed Jan 3, 2017 16:02 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 1,629 | $10.49 | $17,089.19 |
DisclosureSEC source: 0001562180-17-000082 · primarydocument.xml · nonDerivative · entry 1 Dahan Michel · CIK 0001669737 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,524 F1 · shares: Shares sold by reporting person to pay taxes in connection with the vesting of restricted stock pursuant to a December 23, 2013 award. Twenty-five percent of the shares vested on December 2, 2014, and the remaining shares vest in equal quarterly installments through October 1, 2017. Read SEC document |
| October 01, 2016 Filed Oct 4, 2016 16:12 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 1,401 | $8.95 | $12,545.67 |
DisclosureSEC source: 0001562180-16-003207 · primarydocument.xml · nonDerivative · entry 1 Dahan Michel · CIK 0001669737 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,153 F1 · shares: Shares sold by reporting person to pay taxes in connection with the vesting of restricted stock pursuant to a December 23, 2013 award. Twenty-five percent of the shares vested on December 2, 2014, and the remaining shares vest in equal quarterly installments through December 2, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.